Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 16/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 5/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 3/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 0.79 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.79 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL639768 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2BTP53 | |
| SCHEMBL29386433 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2BTP53 | |
| SCHEMBL17825926 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2BTP53 | |
| SCHEMBL17824401 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2BTP53 | |
| SCHEMBL639767 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2BTP53 | |
| SCHEMBL29524548 | 0.93 | ADORA3 (0.87) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL17824486 | 0.90 | ADORA3 (0.82) | ADORA3ADORA2AADORA1ADORA2BTP53 | |
| SCHEMBL640370 | 0.90 | ADORA3 (0.82) | ADORA3ADORA2AADORA1ADORA2BTP53 | |
| SCHEMBL15189014 | 0.90 | ADORA3 (0.82) | ADORA3ADORA2AADORA1ADORA2BTP53 | |
| SCHEMBL640371 | 0.90 | ADORA3 (0.82) | ADORA3ADORA2AADORA1ADORA2BTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790735-B2 | Methanocarba cycloalkyl nucleoside analogues | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-09-07 | — | — | US | disclosed |
| US-20060270629-A1 | Methanocarba cycloalkyl nucleoside analogues | Govt of the U.S.A., represented by the Secretary, Dept of Health & Human Services (US) | 2006-11-30 | — | — | US | disclosed |
| EP-1252160-B1 | METHANOCARBA CYCLOALKYL NUCLEOSIDE ANALOGUES | US GOV HEALTH & HUMAN SERV (US) | 2006-08-16 | — | — | EP | disclosed |
| US-7087589-B2 | Methanocarba cycloakyl nucleoside analogues | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-08-08 | — | — | US | disclosed |
| EP-1368365-A2 | C2,5'-DISUBSTITUTED AND N6,C2,5'-TRISUBSTITUTED ADENOSINE DERIVATIVES AND THEIR DIFFERENT USES | Universiteit Leiden (NL) | 2003-12-10 | — | — | EP | disclosed |
| US-20030216412-A1 | Methanocarba cycloakyl nucleoside analogues | HEALTH AND HUMAN SERVICES, GOVERNMENT OF THE UNITED STATES OF AMERICA, THE, REPRESENTED BY THE SECRETARY, DEPARTMENT OF | 2003-11-20 | — | — | US | disclosed |
| EP-1252160-A1 | METHANOCARBA CYCLOALKYL NUCLEOSIDE ANALOGUES | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2002-10-30 | — | — | EP | disclosed |
| WO-2002070532-A2 | C2,5'-DISUBSTITUTED AND N6,C2,5'-TRISUBSTITUTED ADENOSINE DERIVATIVES AND THEIR DIFFERENT USES | UNIVERSITEIT LEIDEN (NL) | 2002-09-12 | — | — | WO | disclosed |
| WO-2001051490-A1 | METHANOCARBA CYCLOALKYL NUCLEOSIDE ANALOGUES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216412-A1 | Methanocarba cycloakyl nucleoside analogues | P2RY1, ADORA1, ADORA2A | ADORA3 4/4885ADORA2A 3/4885ADORA1 2/4885 |
| US-20060270629-A1 | Methanocarba cycloalkyl nucleoside analogues | ADORA2A, ADORA1, ADORA2B | ADORA3 4/4885ADORA2A 1/4885ADORA1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.